| Distinctive Molecular Risk Factors Between MDS and MDS/AML Defined by ICC |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Comparative Efficacy of Complement Inhibitors in Complement Inhibitor-Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta-Analysis of Randomized Trials |
|
eJHaem |
Myelodysplastic Syndromes (MDS) |
| The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Observational and Genetic Association of Myelodysplastic Syndromes (MDS) and Autoimmune Diseases in Adults |
|
Mediators of Inflammation |
Myelodysplastic Syndromes (MDS) |
| A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Pharmacologic progress in higher-risk MDS: an uphill battle |
|
Expert Opinion on Pharmacotherapy |
Myelodysplastic Syndromes (MDS) |
